Frontiers in Microbiology, 2019 Limited information is available on antimicrobial susceptibility and clonal distribution of Staphylococcus aureus in the Caribbean region. The aims of this study were to determine the prevalence of antimicrobial resistance among S. aureus isolates and to
Luca Guardabassi +9 more
doaj +1 more source
Proteinbindung des Lipoglykopeptid-Antibiotikums Telavancin
, 2018 Telavancin ist ein Lipoglycopeptidantibiotikum, das bei nosokomialen Pneumonien und komplizierten Hautinfektionen eingesetzt wird. Es hat eine hohe antimikrobielle Aktivität gegen zahlreiche grampositive Bakterienstämme inklusive Methicillin- resistente ...
Rammesmayer, Nicole
core
, 2009 Background/Aims Telavancin is a lipoglycopeptide antimicrobial agent which has been approved in Europe and has been recently FDA approved in the United States.
Steven L. Barriere +5 more
core +1 more source
Comparison of Telavancin and Vancomycin Antibiotic Lock Solutions in the Eradication of Biofilm-Producing Staphylococci and Enterococci from Central Venous Catheters [PDF]
, 2016 Purpose: Results of a study of the activity of antibiotic lock solutions of vancomycin and telavancin against biofilm-forming strains of Staphylococcus epidermidis, Enterococcus faecalis, and Staphylococcus aureus are reported. Methods: An established in
Luther, Megan K. +2 more
core +1 more source
Evaluation of Telavancin Activity versus Daptomycin and Vancomycin against Daptomycin-Nonsusceptible Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model [PDF]
, 2012 Daptomycin-nonsusceptible (DNS) Staphylococcus aureus strains have been reported over the last several years. Telavancin is a lipoglycopeptide with a dual mechanism of action, as it inhibits peptidoglycan polymerization/cross-linking and disrupts the ...
Céline Vidaillac +5 more
core +1 more source
New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections
AntibioticsNosocomial central nervous system (CNS) infections with carbapenem- and colistin-resistant Gram-negative and vancomycin-resistant Gram-positive bacteria are an increasing therapeutic challenge. Here, we review pharmacokinetic and pharmacodynamic data and
Roland Nau, Jana Seele, Helmut Eiffert
doaj +1 more source
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens
, 2011 BACKGROUND: Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. METHODS: Two methodologically identical, double-blind studies (0015 and 0019) were conducted involving patients with hospital-acquired pneumonia (HAP) due to gram ...
Lee, Patrick, MD
core +1 more source
Structural Innovations in Vancomycin: Overcoming Resistance and Expanding the Antibacterial Spectrum
OrganicsVancomycin, a cornerstone antibiotic against severe Gram-positive infections, is increasingly challenged by resistance in Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin Enterococcus spp.
Ricardo Cartes-Velásquez +5 more
doaj +1 more source
, 2018 Methicillin-resistant Staphylococcus aureus (MRSA) acquisition in cystic fibrosis (CF) patients confers a worse clinical outcome with increased rate of declined lung function.
Melanie Roch +4 more
core +1 more source
Genomic Insights into Staphylococcus aureus Isolates Exhibiting Diminished Daptomycin Susceptibility
PathogensDaptomycin is one of the last therapeutic resources for multidrug-resistant gram-positive bacteria. Despite its structural similarities with glycopeptides, its mechanisms of action and resistance are different and in some respects are not completely ...
Natalia Gómez-Casanova +3 more
doaj +1 more source